Risk factors for cognitive impairment associated with nonalcoholic fatty liver disease

Cheng ZHOU; Ran JIA; Jingjing WEI; Chenlu ZHAO; Dongfang SHANG; Wenxia ZHAO

doi:10.3969/j.issn.1001-5256.2022.11.031

Volume 38 Issue 11

Nov. 2022

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(11): 2592-2595

PDF( 1863 KB)

Risk factors for cognitive impairment associated with nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2022.11.031

1.
The First Clinical Medical College of Henan University of Chinese Medicine, Zhengzhou 450046, China
2.
Department of Hepatology and Spleen-Stomach, The First Affiliated Hospital of Henan University of Chinese medicine, Zhengzhou 450046, China

Research funding:

General Project of National Natural Science Foundation of China (81473651);

TCM Discipline Construction Project of Characteristic Backbone Disciplines of Henan Province (STG-ZYXKY-2020024)

More Information

Corresponding author: ZHAO Wenxia, zhao-wenxia@163.com(ORCID: 0000-0002-0592-3504)
Received Date: 2022-03-28
Accepted Date: 2022-04-30
Published Date: 2022-11-20

Abstract

Abstract

At present, non-alcoholic fatty liver disease (NAFLD) has become one of the most common chronic liver diseases in the world. Recent studies have shown that varying degrees of central nervous system dysfunction can occur during the progression of NAFLD, including cognitive impairment and emotional imbalance. This article summarizes the main risk factors for NAFLD-related cognitive impairment at different stages, so as to provide a basis and ideas for the early prevention and clinical treatment of this disease.
- Non-alcoholic Fatty Liver Disease,
- Cognition Disorders,
- Risk Factors

FullText(HTML)

References(38)

References

[1]	RINELLA ME. Nonalcoholic fatty liver disease: a systematic review[J]. JAMA, 2015, 313(22): 2263-2273. DOI: 10.1001/jama.2015.5370.
[2]	KENNEDY-MARTIN T, BAE JP, PACZKOWSKI R, et al. Health-related quality of life burden of nonalcoholic steatohepatitis: a robust pragmatic literature review[J]. J Patient Rep Outcomes, 2017, 2: 28. DOI: 10.1186/s41687-018-0052-7.
[3]	DOWARD LC, BALP MM, TWISS J, et al. Development of a patient-reported outcome measure for non-alcoholic steatohepatitis (NASH-CHECK): Results of a qualitative study[J]. Patient, 2021, 14(5): 533-543. DOI: 10.1007/s40271-020-00485-w.
[4]	GBD 2016 Dementia Collaborators. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016[J]. Lancet Neurol, 2019, 18(1): 88-106. DOI: 10.1016/S1474-4422(18)30403-4.
[5]	WEINSTEIN G, ZELBER-SAGI S, PREIS SR, et al. Association of nonalcoholic fatty liver disease with lower brain volume in healthy middle-aged adults in the framingham study[J]. JAMA Neurol, 2018, 75(1): 97-104. DOI: 10.1001/jamaneurol.2017.3229.
[6]	FILIPOVIĆ B, MARKOVIĆ O, ÐURIĆ V, et al. Cognitive changes and brain volume reduction in patients with nonalcoholic fatty liver disease[J]. Can J Gastroenterol Hepatol, 2018, 2018: 9638797. DOI: 10.1155/2018/9638797.
[7]	CELIKBILEK A, CELIKBILEK M, BOZKURT G. Cognitive assessment of patients with nonalcoholic fatty liver disease[J]. Eur J Gastroenterol Hepatol, 2018, 30(8): 944-950. DOI: 10.1097/MEG.0000000000001131.
[8]	TUTTOLOMONDO A, PETTA S, CASUCCIO A, et al. Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcoholic fatty liver disease (NAFLD): a case control study[J]. Cardiovasc Diabetol, 2018, 17(1): 28. DOI: 10.1186/s12933-018-0670-7.
[9]	WEINSTEIN G, DAVIS-PLOURDE K, HIMALI JJ, et al. Non-alcoholic fatty liver disease, liver fibrosis score and cognitive function in middle-aged adults: The Framingham study[J]. Liver Int, 2019, 39(9): 1713-1721. DOI: 10.1111/liv.14161.
[10]	KANEKIYO T, BU G. The low-density lipoprotein receptor-related protein 1 and amyloid-β clearance in Alzheimer's disease[J]. Front Aging Neurosci, 2014, 6: 93. DOI: 10.3389/fnagi.2014.00093.
[11]	NUCERA S, RUGA S, CARDAMONE A, et al. MAFLD progression contributes to altered thalamus metabolism and brain structure[J]. Sci Rep, 2022, 12(1): 1207. DOI: 10.1038/s41598-022-05228-5.
[12]	ALBANESE E, DAVIS B, JONSSON PV, et al. Overweight and obesity in midlife and brain structure and dementia 26 years later: The AGES-Reykjavik study[J]. Am J Epidemiol, 2015, 181(9): 672-679. DOI: 10.1093/aje/kwu331.
[13]	MANTOVANI A, CSERMELY A, PETRACCA G, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2021, 6(11): 903-913. DOI: 10.1016/S2468-1253(21)00308-3.
[14]	ONI ET, AGATSTON AS, BLAHA MJ, et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?[J]. Atherosclerosis, 2013, 230(2): 258-267. DOI: 10.1016/j.atherosclerosis.2013.07.052.
[15]	KLEINRIDDERS A, FERRIS HA, CAI W, et al. Insulin action in brain regulates systemic metabolism and brain function[J]. Diabetes, 2014, 63(7): 2232-2243. DOI: 10.2337/db14-0568.
[16]	ARNOLD SE, ARVANITAKIS Z, MACAULEY-RAMBACH SL, et al. Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums[J]. Nat Rev Neurol, 2018, 14(3): 168-181. DOI: 10.1038/nrneurol.2017.185.
[17]	van ELDEREN SG, de ROOS A, de CRAEN AJ, et al. Progression of brain atrophy and cognitive decline in diabetes mellitus: a 3-year follow-up[J]. Neurology, 2010, 75(11): 997-1002. DOI: 10.1212/WNL.0b013e3181f25f06.
[18]	ZHANG T, SHAW M, CHERBUIN N. Association between type 2 diabetes mellitus and brain atrophy: A Meta-analysis[J]. Diabetes Metab J, 2022. DOI: 10.4093/dmj.2021.0189.[Onlineaheadofprint]
[19]	COBLEY JN, FIORELLO ML, BAILEY DM. 13 reasons why the brain is susceptible to oxidative stress[J]. Redox Biol, 2018, 15: 490-503. DOI: 10.1016/j.redox.2018.01.008.
[20]	BANKS WA, RHEA EM. The blood-brain barrier, oxidative stress, and insulin resistance[J]. Antioxidants (Basel), 2021, 10(11): 1695. DOI: 10.3390/antiox10111695.
[21]	QIAO B, ZHOU Y, MA WJ, et al. Intestinal microflora imbalance in non-alcoholic fatty liver disease[J/CD]. Chin J Liver Dis: Electronic Edition, 2020, 12(4): 29-33. DOI: 10.3969/j.issn.1674-7380.2020.04.005. 乔兵, 周永, 马文洁, 等. 肠道菌群失调在非酒精性脂肪性肝病中研究进展[J/CD]. 中国肝脏病杂志(电子版), 2020, 12(4): 29-33. DOI: 10.3969/j.issn.1674-7380.2020.04.005.
[22]	ARON-WISNEWSKY J, VIGLIOTTI C, WITJES J, et al. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(5): 279-297. DOI: 10.1038/s41575-020-0269-9.
[23]	BRUCE-KELLER AJ, SALBAUM JM, BERTHOUD HR. Harnessing gut microbes for mental health: Getting from here to there[J]. Biol Psychiatry, 2018, 83(3): 214-223. DOI: 10.1016/j.biopsych.2017.08.014.
[24]	DING JH, JIN Z, YANG XX, et al. Role of gut microbiota via the gut-liver-brain axis in digestive diseases[J]. World J Gastroenterol, 2020, 26(40): 6141-6162. DOI: 10.3748/wjg.v26.i40.6141.
[25]	SARKAR A, LEHTO SM, HARTY S, et al. Psychobiotics and the manipulation of bacteria-gut-brain signals[J]. Trends Neurosci, 2016, 39(11): 763-781. DOI: 10.1016/j.tins.2016.09.002.
[26]	LONG-SMITH C, O'RIORDAN K J, CLARKE G, et al. Microbiota-gut-brain axis: New therapeutic opportunities[J]. Annu Rev Pharmacol Toxicol, 2020, 60: 477-502. DOI: 10.1146/annurev-pharmtox-010919-023628.
[27]	SWAIN MG, JONES D. Fatigue in chronic liver disease: New insights and therapeutic approaches[J]. Liver Int, 2019, 39(1): 6-19. DOI: 10.1111/liv.13919.
[28]	GHAREEB DA, HAFEZ HS, HUSSIEN HM, et al. Non-alcoholic fatty liver induces insulin resistance and metabolic disorders with development of brain damage and dysfunction[J]. Metab Brain Dis, 2011, 26(4): 253-267. DOI: 10.1007/s11011-011-9261-y.
[29]	BALZANO T, FORTEZA J, MOLINA P, et al. The cerebellum of patients with steatohepatitis shows lymphocyte infiltration, microglial activation and loss of Purkinje and granular neurons[J]. Sci Rep, 2018, 8(1): 3004. DOI: 10.1038/s41598-018-21399-6.
[30]	VIROVIĆ-JUKI ĆL, STOJSAVLJEVI Ć -SHAPESKI S, FORGA ČJ, et al. Non-alcoholic fatty liver disease-a procoagulant condition?[J]. Croat Med J, 2021, 62(1): 25-33.
[31]	ÖNNERHAG K, NILSSON PM, LINDGREN S. Increased risk of cirrhosis and hepatocellular cancer during long-term follow-up of patients with biopsy-proven NAFLD[J]. Scand J Gastroenterol, 2014, 49(9): 1111-1118. DOI: 10.3109/00365521.2014.934911.
[32]	YOUNOSSI ZM, OTGONSUREN M, HENRY L, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009[J]. Hepatology, 2015, 62(6): 1723-1730. DOI: 10.1002/hep.28123.
[33]	de CHIARA F, HEEBØLL S, MARRONE G, et al. Urea cycle dysregulation in non-alcoholic fatty liver disease[J]. J Hepatol, 2018, 69(4): 905-915. DOI: 10.1016/j.jhep.2018.06.023.
[34]	HIGARZA SG, ARBOLEYA S, GUEIMONDE M, et al. Neurobehavioral dysfunction in non-alcoholic steatohepatitis is associated with hyperammonemia, gut dysbiosis, and metabolic and functional brain regional deficits[J]. PLoS One, 2019, 14(9): e0223019. DOI: 10.1371/journal.pone.0223019.
[35]	LEBOSSÉ F, GUDD C, TUNC E, et al. CD8⁺T cells from patients with cirrhosis display a phenotype that may contribute to cirrhosis-associated immune dysfunction[J]. EBioMedicine, 2019, 49: 258-268. DOI: 10.1016/j.ebiom.2019.10.011.
[36]	FITZPATRICK Z, FRAZER G, FERRO A, et al. Gut-educated IgA plasma cells defend the meningeal venous sinuses[J]. Nature, 2020, 587(7834): 472-476. DOI: 10.1038/s41586-020-2886-4.
[37]	AL-ASMAKH M, HEDIN L. Microbiota and the control of blood-tissue barriers[J]. Tissue Barriers, 2015, 3(3): e1039691. DOI: 10.1080/21688370.2015.1039691.
[38]	KRONSTEN VT, TRANAH TH, PARIANTE C, et al. Gut-derived systemic inflammation as a driver of depression in chronic liver disease[J]. J Hepatol, 2022, 76(3): 665-680. DOI: 10.1016/j.jhep.2021.11.008.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (393) PDF downloads(52)

Risk factors for cognitive impairment associated with nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2022.11.031

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Risk factors for cognitive impairment associated with nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2022.11.031

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content